Purpose: Docetaxel and capecitabine, a tumor-acti-vated oral fluoropyrimidine, show high
single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies. …

S2 cancer in the general population remains unclear. Furthermore, the methodology of ATM
mutation detection is still laborious and costly. Because the ATM protein kinase …

Purpose The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide
(FEC) with a sequential regimen of three cycles of FEC followed by three cycles of …

Purpose Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted monoclonal
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …

Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment
for patients with HER2-positive early-stage breast cancer. However, the optimum duration …

Conclusion: First-course docetaxel PK is a predictor of first-course hematologic toxicity, but
also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes …

Purpose: T-cell infiltration is associated with good tumor prognosis in many cancers. To assess
the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we …

Purpose Recent data showed improvement in progression-free survival (PFS) when adding
everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/…

Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of
naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell …

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR)
of 50% in patients with human epidermal growth factor receptor 2 (HER2)–positive …